In vivo, shRNA-mediated PSAP knockdown in murine PKCY cells increased intratumoral CD8+ T-cells and reduced tumor volume, suggesting that PSAP may promote the progression of PDAC by inhibiting CD8+ T-cells and PSAP modulation may be a potential new strategy for immunotherapy of PDAC [24] (Figure 6). The gene discussed is CD8A; the disease is neoplasm.